Industry associations still resisting non-disclosure agreements for negotiation

July 31, 2026 Latest News BioPharma News of the Day

This is a preview of subscriber content

Subscribe now to continue reading.

Medicines Australia and the Generic and Biosimilar Medicines Association are understood to be maintaining their opposition to non-disclosure deeds as a condition of new agreement negotiations. …

Subscribe now to continue reading.

Latest Video

Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - Latest News
Opportunity #4 - Scope creep demands stronger checks and balances
August 19, 2026 - Latest News
OncoSil secures FDA approval for targeted bile duct cancer device
August 17, 2026 - Latest News
Dimerix takes control of US development pathway for new kidney injury treatment
August 17, 2026 - Australian Biotech
Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches
August 17, 2026 - Australian Biotech

Industry associations still resisting non-disclosure agreements for negotiation

This is a preview of subscriber content

Latest Video

Most Read

Opportunity #1 - biosimilar policy failure has become impossible to ignore

Opportunity #4 - Scope creep demands stronger checks and balances

OncoSil secures FDA approval for targeted bile duct cancer device

Dimerix takes control of US development pathway for new kidney injury treatment

Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches

New Stories

Rare autoimmune diseases impose a $1.2 billion annual burden on Australians

Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm

New Zealand researchers honoured for work tackling superbugs and blood cancer

Novo Nordisk backs care for rural health professionals in southern NSW

Opportunity #3 - finally deliver on the repeated claims of patient-centricity

Departmental restructure formally splits medicines financing from pharmacy services

Wesfarmers Health evolves its loyalty program with new Pulse Rewards

Sign In

Industry associations still resisting non-disclosure agreements for negotiation

This is a preview of subscriber content

Latest Video

Most Read

Opportunity #1 - biosimilar policy failure has become impossible to ignore

Opportunity #4 - Scope creep demands stronger checks and balances

OncoSil secures FDA approval for targeted bile duct cancer device

Dimerix takes control of US development pathway for new kidney injury treatment

Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches

Follow Us

New Stories

Rare autoimmune diseases impose a $1.2 billion annual burden on Australians

Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm

New Zealand researchers honoured for work tackling superbugs and blood cancer

Novo Nordisk backs care for rural health professionals in southern NSW

Opportunity #3 - finally deliver on the repeated claims of patient-centricity

Departmental restructure formally splits medicines financing from pharmacy services

Wesfarmers Health evolves its loyalty program with new Pulse Rewards